Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart ...

AI-powered chatbots will enhance HCP engagement, while comprehensive customer lifetime value prediction will enable more ...

Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...

NHS England has started a pilot trial of an iPhone app and device combination that could be used by nursing staff to speed up reviews of suspected throat cancer. The technology consists of an ...